Atherosclerotic Cardiovascular Disease
📧 Sign up to get email alerts when something new happens for Atherosclerotic Cardiovascular Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-05-17FDA Approved: GEMFIBROZIL — Supplemental Application (Chartwell RX, LLC)
The FDA approved a supplemental application for Gemfibrozil submitted by Chartwell RX, LLC.
-
CLINICAL_TRIALS research · 2024-05-09Clinical Trial Update: Maternal and Offspring Outcomes in Pregnant Women With Pre-existing ASCVD
This clinical trial update indicates that a study at Samsung Medical Center is investigating maternal and offspring outcomes in pregnant wom…
-
CLINICAL_TRIALS research · 2024-05-08Clinical Trial Update: In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
Completed in silico study evaluating the potential impact of inclisiran on major adverse cardiovascular events in patients with established …
-
FDA approval · 2024-04-30FDA Approved: EZETIMIBE — Supplemental Application (Ohm Laboratories Inc.)
The FDA approved a supplemental application for ezetimibe from Ohm Laboratories Inc., updating the regulatory status of the product.
-
FDA approval · 2024-04-30FDA Approved: PITAVASTATIN CALCIUM — Original Application (NorthStar RxLLC)
FDA approved NorthStar RxLLC's original application for pitavastatin calcium, a generic statin, to treat hyperlipidemia by lowering choleste…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-04-04FDA Approved: PITAVASTATIN — Supplemental Application (Teva Pharmaceuticals, Inc.)
FDA approved Teva's supplemental application for pitavastatin calcium (pitavastatin) under ANDA205932.
-
FDA approval · 2024-04-02FDA Approved: LIPITOR — Supplemental Application (Viatris Specialty LLC)
FDA has approved a supplemental application for Lipitor (atorvastatin calcium) submitted by Viatris Specialty LLC to update labeling.
-
FDA approval · 2024-03-29FDA Approved: EZETIMIBE — Supplemental Application (Quallent Pharmaceuticals Health LLC)
The FDA approved a supplemental application for ezetimibe filed by Quallent Pharmaceuticals Health LLC. This confirms approval of a new or m…
-
CLINICAL_TRIALS trial_result · 2024-03-25Clinical Trial Update: Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support [Phase 3]
Novartis completed a Phase 3 trial evaluating how inclisiran is delivered in primary care with enhanced support, focusing on implementation …
-
FDA approval · 2024-03-20FDA Approved: EZALLOR SPRINKLE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for EZALLOR SPRINKLE (rosuvastatin) by Sun Pharmaceutical Industries, expanding its approved ros…
-
FDA approval · 2024-03-14FDA Approved: LIVALO — Supplemental Application (Kowa Pharmaceuticals America, Inc.)
FDA approved a supplemental application for LIVALO (pitavastatin calcium) submitted by Kowa Pharmaceuticals America, Inc.
-
FDA approval · 2024-03-12FDA Approved: ROSUVASTATIN — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA supplemental approval has been granted for rosuvastatin from Camber Pharmaceuticals, indicating an approved supplemental application for…
-
FDA approval · 2024-03-08FDA Approved: PRALUENT — Supplemental Application (Regeneron Pharmaceuticals, Inc.)
FDA approved Regeneron's supplemental application for PRALUENT (alirocumab), confirming expanded regulatory authorization.
-
CLINICAL_TRIALS trial_result · 2024-03-06Clinical Trial Update: Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C [Phase 3]
Phase 3 trial update evaluating long-term dosing of inclisiran in high cardiovascular risk patients with elevated LDL-C; study completed wit…
-
FDA approval · 2024-02-21FDA Approved: ZETIA — Supplemental Application (Organon LLC)
FDA approved a supplemental application for Zetia (ezetimibe) from Organon LLC.
-
CLINICAL_TRIALS trial_result · 2024-02-20Clinical Trial Update: Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events
A completed clinical trial update on preventing cardiovascular events in patients with high to very high risk dyslipidemia; results posted i…
-
FDA approval · 2024-02-16FDA Approved: ICOSAPENT ETHYL — Original Application (Northstar Rx LLC)
FDA approved the original application for icospent ethyl (ICOSAPENT ETHYL) from Northstar Rx LLC, a generic version of the prescription ther…
-
FDA approval · 2024-02-08FDA Approved: VYTORIN — Supplemental Application (Organon LLC)
The FDA approved a supplemental application for VYTORIN (ezetimibe and simvastatin) submitted by Organon LLC.
-
FDA approval · 2024-02-02FDA Approved: ROSUVASTATIN CALCIUM — Supplemental Application (Glenmark Pharmaceutials Inc., USA)
FDA approved a supplemental application for Rosuvastatin Calcium submitted by Glenmark Pharmaceuticals Inc., USA.
-
FDA approval · 2024-01-31FDA Approved: SIMVASTATIN — Supplemental Application (NorthStar Rx LLC)
FDA approves a supplemental application for simvastatin from NorthStar Rx LLC (ANDA).
-
FDA approval · 2024-01-30FDA Approved: EZETIMIBE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for ezetimibe from Sandoz Inc., authorizing the continued availability of a generic ezetimibe produc…
-
FDA approval · 2024-01-16FDA Approved: SIMVASTATIN — Supplemental Application (Biocon Pharma Inc,)
FDA approved Biocon Pharma's supplemental application for simvastatin (ANDA078034), approving a generic simvastatin product filing.
-
FDA approval · 2024-01-05FDA Approved: ROSUVASTATIN — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for rosuvastatin from Accord Healthcare Inc. (ANDA 206434).
-
FDA approval · 2024-01-05FDA Approved: ATORVASTATIN CALCIUM — Original Application (NorthStar RxLLC)
FDA approved NorthStar RxLLC's generic atorvastatin calcium under an original ANDA.
-
CLINICAL_TRIALS trial_result · 2023-12-27Clinical Trial Update: Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis [NA]
Pilot study assessing the effect of nicotinamide riboside on immune activation in psoriasis; study completed with results posted.